ALX Oncology Shares Drop 15% Following Positive Phase 2

ALX Oncology Holdings Inc. (ALXO, Financials) saw its stock price fall 15.8% to $1.52 as of 2:32 p.m. GMT-5 on Thursday, despite announcing positive updated results from its ASPEN-06 Phase 2 clinical trial.